Understanding responder neurobiology in schizophrenia using a quantitative systems pharmacology model: Application to iloperidone

Journal of Psychopharmacology

Volumn 29, Issue 4, 2015, Pages 372-382

  Geerts, Hugo ^a,b   Roberts, Patrick ^a,c   Spiros, Athan ^a   Potkin, Steven ^d  

^a In Silico BioSciences   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Quantitative systems pharmacology; responder population; targeted therapies

Indexed keywords

4 AMINOBUTYRIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; DOPAMINE 4 RECEPTOR; ILOPERIDONE; PLACEBO; RECEPTOR ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; SEROTONIN 3 RECEPTOR; UNCLASSIFIED DRUG; ZIPRASIDONE; ISOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENOTYPE; GRIA4 GENE; HUMAN; IMAGE ANALYSIS; INVESTIGATIVE PROCEDURES; MOLECULAR IMAGING; NERVE CELL NETWORK; NEUROIMAGING; OUTCOME ASSESSMENT; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PSYCHOPHARMACOLOGY; QUANTITATIVE ANALYSIS; QUANTITATIVE SYSTEM PHARMACOLOGY; RETROSPECTIVE STUDY; SCHIZOPHRENIA; BIOLOGICAL MODEL; COMPARATIVE STUDY; COMPUTER SIMULATION; MOLECULARLY TARGETED THERAPY; NEUROBIOLOGY; PATHOPHYSIOLOGY; PHARMACOGENETICS; PROCEDURES;

ANTIPSYCHOTIC AGENTS; COMPUTER SIMULATION; GENOTYPE; HUMANS; ISOXAZOLES; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEUROBIOLOGY; PHARMACOGENETICS; PIPERAZINES; PIPERIDINES; SCHIZOPHRENIA; THIAZOLES;

EID: 84924953683     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881114568042     Document Type: Article

References (68)

1. Alkondon M, Albuquerque EX. Nicotinic acetylcholine receptor alpha7 and alpha4beta2 subtypes differentially control GABAergic input to CA1 neurons in rat hippocampus. J Neurophysiol. 2001 ; 86: 3043-3055
2. Alphs L, Benedetti F, Fleischhacker WW, et al. Placebo-related effects in clinical trials in schizophrenia: What is driving this phenomenon and what can be done to minimize it?. Int J Neuropsychopharmacol. 2012 ; 15: 1-12
3. Ansanay H, Dumuis A, Sebben M, et al. cAMP-dependent, long-lasting inhibition of a K+ current in mammalian neurons. Proc Natl Acad Sci U S A. 1995 ; 92: 6635-6639
4. Aracri P, Consonni S, Morini R, et al. Tonic modulation of GABA release by nicotinic acetylcholine receptors in layer V of the murine prefrontal cortex. Cereb Cortex. 2010 ; 20: 1539-1555
5. Arnsten AF, Murphy B, Merchant K. The selective dopamine D4 receptor antagonist, PNU-101387G, prevents stress-induced cognitive deficits in monkeys. Neuropsychopharmacology. 2000 ; 23: 405-410
6. Athan Spiros HG. A quantitative way to estimate clinical off-target effects for human membrane brain targets in CNS research and development. J Exp Pharmacology. 2012 ; 4: 53-62
7. Bobo WV. Asenapine, iloperidone and lurasidone: Critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013 ; 6: 61-91
8. Boehm S. Presynaptic alpha2-adrenoceptors control excitatory, but not inhibitory, transmission at rat hippocampal synapses. J Physiol. 1999 ; 519 (Pt 2). 439-449
9. Box G Statistics for Experimenters: Design, Innovation, and Discovery. 2005 ) Statistics for Experimenters: Design, Innovation, and Discovery. 2nd ed. Hoboken, NJ: Wiley and Sons. Hoboken, NJ: Wiley and Sons ; 2005 :
10. Cai X, Flores-Hernandez J, Feng J, et al. Activity-dependent bidirectional regulation of GABA(A) receptor channels by the 5-HT(4) receptor-mediated signalling in rat prefrontal cortical pyramidal neurons. J Physiol. 2002 ; 540: 743-759
11. Cardenas CG, Del Mar LP, Scroggs RS. Two parallel signaling pathways couple 5HT1A receptors to N- and L-type calcium channels in C-like rat dorsal root ganglion cells. J Neurophysiol. 1997 ; 77: 3284-3296
12. Carr DB, Cooper DC, Ulrich SL, et al. Serotonin receptor activation inhibits sodium current and dendritic excitability in prefrontal cortex via a protein kinase C-dependent mechanism. J Neurosci. 2002 ; 22: 6846-6855
13. Citrome L, Meng X, Hochfeld M, et al. Efficacy of iloperidone in the short-term treatment of schizophrenia: A post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials. Hum Psychopharmacol. 2012 ; 27: 24-32
14. Corrigan MH, Gallen CC, Bonura ML, et al. Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: A placebo-controlled trial. Biol Psychiatry. 2004 ; 55: 445-451
15. Coyle JT. Glutamate and schizophrenia: Beyond the dopamine hypothesis. Cell Mol Neurobiol. 2006 ; 26: 365-384
16. DeFelipe J. Cortical interneurons: From Cajal to 2001. Prog Brain Res. 2002 ; 136: 215-238
17. Durstewitz D, Seamans JK. The dual-state theory of prefrontal cortex dopamine function with relevance to catechol-o-methyltransferase genotypes and schizophrenia. Biol Psychiatry. 2008 ; 64: 739-749
18. Durstewitz D, Seamans JK, Sejnowski TJ. Dopamine-mediated stabilization of delay-period activity in a network model of prefrontal cortex. J Neurophysiol. 2000 ; 83: 1733-1750
19. Elvevag B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol. 2000 ; 14: 1-21
20. Foehring RC. Serotonin modulates N- and P-type calcium currents in neocortical pyramidal neurons via a membrane-delimited pathway. J Neurophysiol. 1996 ; 75: 648-659
21. Geerts H. Of mice and men: Bridging the translational disconnect in CNS drug discovery. CNS Drugs. 2009 ; 23: 915-926
22. Geerts H. alpha7 nicotinic receptor modulators for cognitive deficits in schizophrenia and Alzheimer's disease. Expert Opin Investig Drugs. 2012 ; 21: 59-65
23. Geerts H, Roberts P, Spiros A. A quantitative system pharmacology computer model for cognitive deficits in schizophrenia. CPT Pharmacometrics Syst Pharmacol. 2013a ; 2: e36
24. Geerts H, Spiros A, Roberts P, et al. Has the time come for predictive computer modeling in CNS drug discovery and development?. CPT Pharmacometrics Syst Pharmacol. 2012a ; 1: e16
25. Geerts H, Spiros A, Roberts P, et al. Quantitative systems pharmacology as an extension of PK/PD modeling in CNS research and development. J Pharmacokinet Pharmacodyn. 2013b ; 40: 257-265
26. Geerts H, Spiros A, Roberts P, et al. Blinded prospective evaluation of computer-based mechanistic schizophrenia disease model for predicting drug response. PLoS ONE. 2012b ; 7: e49732
27. Gerhardt CC, van Heerikhuizen H. Functional characteristics of heterologously expressed 5-HT receptors. Eur J Pharmacol. 1997 ; 334: 1-23
28. Harvey PO, Armony J, Malla A, et al. Functional neural substrates of self-reported physical anhedonia in non-clinical individuals and in patients with schizophrenia. J Psychiatr Res. 2010 ; 44: 707-716
29. Keitner GI, Mansfield AK. Management of treatment-resistant depression. Psychiatr Clin North Am. 2012 ; 35: 249-265
30. Kurtz MM, Moberg PJ, Gur RC, et al. Approaches to cognitive remediation of neuropsychological deficits in schizophrenia: A review and meta-analysis. Neuropsychol Rev. 2001 ; 11: 197-210
31. Lavedan C, Licamele L, Volpi S, et al. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol Psychiatry. 2009 ; 14: 804-819
32. Law-Tho D, Hirsch JC, Crepel F. Dopamine modulation of synaptic transmission in rat prefrontal cortex: An in vitro electrophysiological study. Neurosci Res. 1994 ; 21: 151-160
33. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet. 2013 ; 382: 951-962
34. Levy R, Goldman-Rakic PS. Segregation of working memory functions within the dorsolateral prefrontal cortex. Exp Brain Res. 2000 ; 133: 23-32
35. Liu J, Ogden A, Comery TA, et al. Prediction of efficacy of vabicaserin, a 5-HT2C agonist, for the treatment of schizophrenia using a quantitative systems pharmacology model. CPT Pharmacometrics Syst Pharmacol. 2014 ; 3: e111
36. Makino C, Fujii Y, Kikuta R, et al. Positive association of the AMPA receptor subunit GluR4 gene (GRIA4) haplotype with schizophrenia: Linkage disequilibrium mapping using SNPs evenly distributed across the gene region. Am J Med Genet B Neuropsychiatr Genet. 2003 ; 116B: 17-22
37. Mansbach RS, Brooks EW, Sanner MA, et al. Selective dopamine D4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition. Psychopharmacology (Berl). 1998 ; 135: 194-200
38. Meyer-Lindenberg A, Miletich RS, Kohn PD, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci. 2002 ; 5: 267-271
39. Moghaddam B, Bolinao ML. Glutamatergic antagonists attenuate ability of dopamine uptake blockers to increase extracellular levels of dopamine: Implications for tonic influence of glutamate on dopamine release. Synapse. 1994 ; 18: 337-342
40. Murai T, Nakako T, Ikeda K, et al. Lack of dopamine D4 receptor affinity contributes to the procognitive effect of lurasidone. Behav Brain Res. 2014 ; 261: 26-30
41. Nicholas T, Duvvuri D, Leurent C, et al. Systems pharmacology modeling in neuroscience: Prediction and outcome of PF-04995274, a 5HT4 partial agonist, in a Clinical Scopolamine Impairment Trial. Advances in Alzheimer's Disease. 2013 ; 2: 83-98
42. Okuda H, Tatsumi K, Morita S, et al. The chondroitin sulfate proteoglycan tenascin-R regulates glutamate uptake by adult brain astrocytes. J Biol Chem. 2014 ; 289: 2620-2631
43. Parikh V, Ji J, Decker MW, et al. Prefrontal beta2 subunit-containing and alpha7 nicotinic acetylcholine receptors differentially control glutamatergic and cholinergic signaling. J Neurosci. 2010 ; 30: 3518-3530
44. Parnas H, Slutsky I, Rashkovan G, et al. Depolarization initiates phasic acetylcholine release by relief of a tonic block imposed by presynaptic M2 muscarinic receptors. J Neurophysiol. 2005 ; 93: 3257-3269
45. Perez-Rosello T, Figueroa A, Salgado H, et al. Cholinergic control of firing pattern and neurotransmission in rat neostriatal projection neurons: Role of CaV2.1 and CaV2.2 Ca2+ channels. J Neurophysiol. 2005 ; 93: 2507-2519
46. Plackett W, Burman P. The design of optimal multifactorial experiments. Biometrika. 1946 ; 33: 325-336
47. Potkin SG, Litman RE, Torres R, et al. Efficacy of iloperidone in the treatment of schizophrenia. J Clin Psychopharmacol. 2008 ; 28: S4 - S11
48. Puig MV, Santana N, Celada P, et al. In vivo excitation of GABA interneurons in the medial prefrontal cortex through 5-HT3 receptors. Cereb Cortex. 2004 ; 14: 1365-1375
49. Reif A, Schmitt A, Fritzen S, et al. Neurogenesis and schizophrenia: Sividing neurons in a divided mind?. Eur Arch Psychiatry Clin Neurosci. 2007 ; 257: 290-299
50. Riemer C, Borroni E, Levet-Trafit B, et al. Influence of the 5-HT6 receptor on acetylcholine release in the cortex: Pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist. J Med Chem. 2003 ; 46: 1273-1276
51. Roberts PD, Spiros A, Geerts H. Simulations of symptomatic treatments for Alzheimer's disease: Computational analysis of pathology and mechanisms of drug action. Alzheimers Res Ther. 2012 ; 4: 50
52. Saykin AJ, Shtasel DL, Gur RE, et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry. 1994 ; 51: 124-131
53. Shen W, Hamilton SE, Nathanson NM, et al. Cholinergic suppression of KCNQ channel currents enhances excitability of striatal medium spiny neurons. J Neurosci. 2005 ; 25: 7449-7458
54. Singh SP, Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs. 2011 ; 25: 859-885
55. Slifstein M, Kolachana B, Simpson EH, et al. COMT genotype predicts cortical-limbic D1 receptor availability measured with [11C]NNC112 and PET. Mol Psychiatry. 2008 ; 13: 821-827
56. Spiros A, Carr R, Geerts H. Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse. Neuropsychiatr Dis Treat. 2010 ; 6: 589-603
57. Spiros A, Roberts P, Geerts H. A quantitative systems pharmacology computer model for schizophrenia efficacy and extrapyramidal side effects. Drug Development Research. 2012 ; 73: 196-213
58. Thompson A, Lavedan C, Volpi S. Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone. Psychiatry Res. 2010 ; 175: 271-273
59. Tseng KY, O'Donnell P. D2 dopamine receptors recruit a GABA component for their attenuation of excitatory synaptic transmission in the adult rat prefrontal cortex. Synapse. 2007 ; 61: 843-850
60. Volk DW, Lewis DA. Impaired prefrontal inhibition in schizophrenia: Relevance for cognitive dysfunction. Physiol Behav. 2002 ; 77: 501-505
61. Volpi S, Heaton C, Mack K, et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol Psychiatry. 2009 ; 14: 1024-1031
62. Watts A, Watts M, Snelling J Seeds of Genius: The Early Writings of Alan Watts. Shaftesbury, Rockport: Element Books ; 1997 :
63. Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature. 1995 ; 376: 572-575
64. Winterer G, Ziller M, Dorn H, et al. Schizophrenia: Reduced signal-to-noise ratio and impaired phase-locking during information processing. Clin Neurophysiol. 2000 ; 111: 837-849
65. Yuen EY, Liu W, Kafri T, et al. Regulation of AMPA receptor channels and synaptic plasticity by cofilin phosphatase Slingshot in cortical neurons. J Physiol. 2010 ; 588: 2361-2371
66. Yuen EY, Yan Z. Dopamine D4 receptors regulate AMPA receptor trafficking and glutamatergic transmission in GABAergic interneurons of prefrontal cortex. J Neurosci. 2009 ; 29: 550-562
67. Yuen EY, Yan Z. Cellular mechanisms for dopamine D4 receptor-induced homeostatic regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. J Biol Chem. 2011 ; 286: 24957-24965
68. Zhang W, Yamada M, Gomeza J, et al. Multiple muscarinic acetylcholine receptor subtypes modulate striatal dopamine release, as studied with M1-M5 muscarinic receptor knock-out mice. J Neurosci. 2002 ; 22: 6347-6352